INTRODUCTION Zinc chelators were shown to facilitate some opioid-withdrawal signs in animals. Zinc deficiency, which affects more than 15% the world's population, is also common among opioid consumers and opioid-treated animals exhibit misbalances of zinc distribution. AIM The present study focuses on how zinc ions interfere with opioid dependence/addiction and analgesia, trying to preliminar...

Pethidine is a synthetic opioid substance with high addiction potential. It is commonly used in medicine pre and postoperatively to relieve the pain. A Pethidine addiction generally starts as iatrogenic and may be a problem for the clinicians when there is a real pain. Its opioid analgesic usage is legal, yet it is possible that it can be abused by the health care workers and addiction may beco...

BACKGROUND The opioid receptor antagonists naloxone and naltrexone are competitive antagonists at the mu, kappa, and sigma receptors with a higher affinity for the mu receptor and lacking any mu receptor efficacy. Buprenorphine is classified as a partial agonist. It has a high affinity, but low efficacy at the mu receptor where it yields a partial effect upon binding. It also, however, possesse...

Synthetic opioid agents have been used in modern medicine for over a century and for opioid addiction treatment for over a half-century. Liberal use of opioids in the United States has been attended by an extraordinary increase in opioid-related mortality, with over 16,000 deaths in 2012. As there have been advances in opioid agents for pain and addiction, so have there been advances in our und...

Opioid addiction has become a global epidemic and a national health crisis in recent years, with the number of opioid overdose fatalities steadily increasing since the 1990s. In contrast to the dynamics of a typical illicit drug or disease epidemic, opioid addiction has its roots in legal, prescription medication a fact which greatly increases the exposed population and provides additional drug...

Three reviews in the Frontiers Research Topic "Non-Coding RNA and Addiction" (He and Wang, 2012; Rodriguez, 2012; Zheng et al., 2012), grouped under the chapter "MicroRNAs and Morphine," focus on the contribution of microRNAs to opioid abuse. Although animal models have been fundamental to our understanding of addiction pathways, the assumption that microRNAs implicated in opioid tolerance - an...

Opioid agonists are the most effective treatment for pain, but their use is limited by side effects, tolerance and fears of addiction and dependence. A major goal of opioid research is to develop agonists that have high analgesic efficacy and a low profile for side effects, tolerance, addiction and dependence. Unfortunately, there is a serious lack of experimental data comparing the degree to w...

background: high prevalence of risky behaviors in alcohol dependents have been shown in several studies, but correlation between alcohol abuse and risky behaviors and relapse in patients with opiate dependence has been less investigated. this study aimed to determine the effect of alcohol abuse in rate of risk-taking behaviors in opiate dependents patients treated on maintenance program in nort...

BACKGROUND Some bioethicists have questioned whether opioid addicted individuals are able to provide free and informed consent to opioid agonist maintenance treatment. Conflicting motives for providing such treatment (e.g. improving the personal health of addicts and protecting public health and order) can also influence what individuals are required to consent to, and how that consent is obtai...

BACKGROUND AND OBJECTIVES Opioid abuse and dependence are increasing. Pharmacotherapy with an opioid agonist reduces adverse consequences of opioid dependency. Physicians can now prescribe buprenorphine for opioid dependency in the primary care setting. This study assessed primary care providers' attitudes and beliefs about opioid addiction treatment with buprenorphine. METHODS Ninety-nine re...